“The function of gp130-mediated signaling pathways in the heart and how they may affect prospective treatment areas”

Cytokines of the IL-6 type attach themselves to complexes of plasma membrane receptors that contain the common signal transducing receptor chain, or Gp130, which is present in most organs, including the heart. It has been shown that the two main signaling cascades that the Gp130 receptor activates, the SHP2/ERK and STAT pathways, are crucial for the growth, hypertrophy, protection, and remodeling of the heart in response to normal and pathological stimuli. Experimental evidence suggests that Gp130 signaling promotes the proliferation and survival of cardiomyocytes in both in vitro and in vivo settings. On the other hand, it has been documented that in individuals with heart failure or following a myocardial infarction, increased serum levels of Gp130 proteins and IL-6 cytokines are robust predictors of morbidity and death. Furthermore, it has been demonstrated that failing human hearts have changes to the localgp130 receptor system. In The basic concepts of Gp130 signaling are outlined in this article. A balanced biological outcome needs the simultaneous activation of the STAT and ERK pathways, which is tightly regulated by positive and negative intracellular signaling modulators. Additionally, we draw attention to the critical roles that the Gp130 receptor and its main downstream effectors play in the heart's development and regeneration as well as in how it responds to different physiological and pathological stress scenarios. Lastly, we discuss the difficulties and variety among tissues in targeted pharmacological interference with Gp130 receptor system components.

Author(s): Dr. Hari Prasad Sonwani, Dr. Alka Sen, Dr. Seema Kishor Kumar and Dr. Ritu Sahu

Abstract | PDF

Share This Article